Toll-like receptor

Ascendis Pharma A/S Presents New Non-Clinical Data for TransCon™ TLR7/8 Agonist Oncology Program at SITC 2021

Retrieved on: 
Dienstag, November 9, 2021
Safety, SITC, Index (publishing), Science, TLR, Neoplasm, Toll-like receptor, U.S. Securities and Exchange Commission, Hormone, Resiquimod, Technology, Society, Investment, Pembrolizumab, COVID-19, MTD, Research, Forward-looking statement, Annual report, Maxima and minima, Southern Transcon, Society for Immunotherapy of Cancer, GLOBE, SEC, Toxicity, Immunotherapy, B cell, Nasdaq, Patient, Autoinjector, Vaccine, Pharmaceutical industry, Fine chemical

COPENHAGEN, Denmark, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced two poster presentations featuring new non-clinical data for its investigational TransCon™ TLR7/8 Agonist product candidate at SITC 2021, the annual meeting for the Society for Immunotherapy of Cancer taking place virtually and in person November 10-14 in Washington, D.C.

Key Points: 
  • The data show that, as designed, TransCon TLR7/8 Agonist, which leverages the Companys innovative TransCon hydrogel technology, provides sustained activation of both innate and adaptive immune mechanisms with low systemic cytokine levels.
  • Ascendis Pharma is currently conducting a Phase 1/2 study, called the transcendIT-101 Study (ClinicalTrials.gov Identifier: NCT04799054), to evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose expansion cohorts.
  • Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients lives.
  • Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and SKYTROFA are trademarks owned by the Ascendis Pharma Group.

Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers

Retrieved on: 
Mittwoch, Oktober 27, 2021
Safety, Science, SAD, MAD, MD, Biotechnology, Entrepreneurship, LinkedIn, Toll-like receptor, Drug development, Boston Business Journal, TLR, Twitter, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Investor, Lymphatic system, Boston, Receptor (biochemistry), Risk, Sanofi, Conference, International, Atopic dermatitis, Adult, PK, Multiple, Clinical trial, Webcast, CEO, COVID-19, Inflammation, Conference call, MidOcean Partners, Hidradenitis suppurativa, Pharmacokinetics, Nasdaq, Therapy, Rheumatoid arthritis, Doctor of Philosophy, STAT3, Plasma, Pharmaceutical industry, Fine chemical

WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new safety, pharmacokinetic (PK) and pharmacodynamic (PD) data, including cytokines, from the Single Ascending Dose (SAD) portion of the KT-474 Phase 1 randomized, placebo-controlled healthy volunteer trial, at the 4th Annual Targeted Protein Degradation Summit.

Key Points: 
  • In July 2021, Kymera initiated dosing of healthy volunteers in the Multiple Ascending Dose (MAD) portion of the Phase 1 trial of KT-474.
  • The multiple ascending dose portion of the trial is designed to evaluate repeat daily dosing of KT-474 for 14 days, beginning with the 25 mg dose, in healthy volunteers randomized 9:3 to KT-474 or placebo.
  • Kymera plans to present data from the MAD portion of the healthy volunteer study before year end.
  • IRAK4 is a key protein involved in inflammation mediated by the activation of toll-like receptors (TLRs) and IL-1 receptors (IL-1Rs).

Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit

Retrieved on: 
Mittwoch, Oktober 13, 2021
Lymphatic system, Human, SAD, PK, Rheumatoid arthritis, Single, Multiple, Private Securities Litigation Reform Act, Nasdaq, Plenary session, LinkedIn, Risk, MidOcean Partners, Toll-like receptor, Security (finance), Doctor of Philosophy, Adult, TPD, MAD, Cytokine, PD, Therapy, Sanofi, Inflammation, Patient, Science, GLOBE, Hidradenitis suppurativa, Biotechnology, Boston Business Journal, Company, U.S. Securities and Exchange Commission, Annual report, Keynote, CEO, STAT3, Receptor (biochemistry), Boston, Twitter, MD, Safety, NASDAQ, Atopic dermatitis, Entrepreneurship, Pharmacokinetics, COVID-19, Vaccine, Pharmaceutical industry, Fine chemical

A Keynote Plenary Session presentation will include safety, pharmacokinetic (PK) and pharmacodynamic (PD) data, including cytokines, from the Single Ascending Dose (SAD) portion of the KT-474 Phase 1 trial in healthy volunteers that has recently completed dose escalation.

Key Points: 
  • A Keynote Plenary Session presentation will include safety, pharmacokinetic (PK) and pharmacodynamic (PD) data, including cytokines, from the Single Ascending Dose (SAD) portion of the KT-474 Phase 1 trial in healthy volunteers that has recently completed dose escalation.
  • We look forward to presenting PK and PD data, including IRAK4 levels and cytokine results, from the SAD portion of the KT-474 Phase 1 randomized, placebo-controlled trial in healthy volunteers.
  • Additionally, while we have completed Single Ascending Dose escalation, the Multiple Ascending Dose (MAD) portion of the trial continues in healthy volunteers.
  • We plan to present data from the MAD portion of our healthy volunteer Phase 1 study before year-end.

Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results

Retrieved on: 
Mittwoch, August 25, 2021
Toll-like receptor, Parathyroid hormone, European, U.S. Securities and Exchange Commission, Cmax, Achondroplasia, Technology, SEC, Growth hormone, European Medicines Agency, Science, Research, Food, Marketing Authorisation Application, Disease, Hypoparathyroidism, CNP, Resiquimod, Hormone, Forward-looking statement, Autoinjector, Investment, Review, Investor, GHD, IND, Safety, Marketing, Patient, OLE, Bias, TLR, ACH, FDA, Neoplasm, Degenerative disease, Clinician Administered PTSD Scale, COVID-19, Annual report, PTH, Dwarfism, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Tutoring

COPENHAGEN, Denmark, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ lives, today announced financial results for the second quarter ended June 30, 2021.

Key Points: 
  • TransCon CNP is designed to provide continuous exposure of CNP at safe, therapeutic levels via a single, weekly subcutaneous dose.
  • Ascendis Pharma currently has a pipeline of multiple independent endocrinology rare disease and oncology product candidates in development.
  • SKYTROFA, Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group.
  • August 2021 Ascendis Pharma A/S.

Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement

Retrieved on: 
Donnerstag, August 12, 2021
TLR9, NASDAQ, Degenerative disease, Multiple sclerosis, AIMS, Autoimmunity, Rheumatoid arthritis, History, Crohn's disease, Neutropenia, Radiation Sickness, CEO, Drug development, Risk, Disease, Science, Cancer, TLR5, COVID-19, Toll-like receptor, Infection, Immune system, La Jolla Institute for Immunology, SEC, Research, Virus, Laboratory, Asthma, Pancreatic cancer, Antibody, Immunity, Health, Coronavirus, Patient, Annual report, Receptor (biochemistry), Growth, European Union, Exercise, Technology, Cleveland, Union, La Jolla, Homeostasis, Fibromyalgia, Budget, Institute, Knowledge, Anemia, Vaccine, Therapy, Hematology, Biomedical Research, TLR4, Cleveland BioLabs, Pharmaceutical industry

Working with the La Jolla Institute, we will deeply explore the mechanisms that we believe will drive next-generation therapeutic development with our AIMS technology and bring hope to patients and their families battling serious medical conditions."

Key Points: 
  • Working with the La Jolla Institute, we will deeply explore the mechanisms that we believe will drive next-generation therapeutic development with our AIMS technology and bring hope to patients and their families battling serious medical conditions."
  • Under the terms of the research agreement, the La Jolla Institute may select up to four laboratories to participate in research.
  • Cytocom will also provide researchers at the La Jolla Institute with samples and materials.
  • Founded in 1988, La Jolla Institute for Immunology is a nonprofit, independent biomedical research institute focused on improving human health through increased understanding of the immune system.

Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger

Retrieved on: 
Dienstag, Juli 6, 2021
Branches of biology, Cleveland BioLabs, Prospectus, Immune receptor, Proxy, Toll-like receptor, Registration statement, Corporate finance

Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs.

Key Points: 
  • Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs.
  • Cleveland BioLabs' proprietary platform of Toll-like immune receptor activators addresses conditions such as radiation sickness and cancer treatment side effects.
  • Cleveland BioLabs has filed a Registration Statement on Form S-4 containing a proxy statement/prospectus of Cleveland BioLabs and other documents concerning the proposed merger with the SEC.
  • The actual future results of Cleveland BioLabs or Cytocom may differ materially from those discussed here for various reasons.

Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo® (cemiplimab)

Retrieved on: 
Montag, Mai 10, 2021
Clusters of differentiation, Branches of biology, TLR9, CPG, Toll-like receptor, CPG

Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component.

Key Points: 
  • Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component.
  • The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information.
  • This list of channels may be updated from time to time on our investor relations website and may include additional social media channels.
  • All information in this press release is as of the date of the release, and Checkmate undertakes no duty to update this information unless required by law.\n'

Tallac Therapeutics Presents New Data on Toll-like Receptor Agonist Antibody Conjugate, TAC-001, at the 2021 Virtual Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Samstag, April 10, 2021
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Medical specialties, Branches of biology, Clinical medicine, Immune system, Immunology, TLR9, Lymphatic system, Toll-like receptor, Immunotherapy, Immunity, Lymphocyte, TAC-001, Tallac Therapeutics, Inc.

The data will be presented today as part of the Immunomodulatory Agents and Interventions Session at Week I of the American Association of Cancer Researchs (AACR) 2021 Virtual Annual Meeting (#AACR21) taking place April 10-15, 2021.

Key Points: 
  • The data will be presented today as part of the Immunomodulatory Agents and Interventions Session at Week I of the American Association of Cancer Researchs (AACR) 2021 Virtual Annual Meeting (#AACR21) taking place April 10-15, 2021.
  • TLR9 is a key intracellular TLR present in broad immune cell populations such as B lymphocytes and myeloid cells.
  • Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer.
  • TAC-001, a toll-like receptor 9 (TLR9) agonist antibody conjugate targeting B cells, promotes anti-tumor immunity and favorable safety profile following systemic administration in preclinical models.

Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update

Retrieved on: 
Donnerstag, März 11, 2021
Medical specialties, Branches of biology, Immunology, Clinical medicine, Immune system, Interleukin-1 receptor associated kinase, IRAK4, Toll-like receptor, Single-pass transmembrane proteins, Immune receptor, Inflammation

We continue to execute against our ambitious goal to build Kymera into a fully integrated, best-in-class degrader medicines company, said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics.

Key Points: 
  • We continue to execute against our ambitious goal to build Kymera into a fully integrated, best-in-class degrader medicines company, said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics.
  • IRAK4 is a key protein involved in inflammation mediated by the activation of toll-like receptors (TLRs) and IL-1 receptors (IL-1Rs).
  • Cash and Cash Equivalents: As of December 31, 2020, Kymera had approximately $458.7 million in cash, cash equivalents, and investments.
  • Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Primmune Therapeutics Announces Close of Series A Financing

Retrieved on: 
Dienstag, Januar 12, 2021
Professional services, Health, Finance, Banking, Pharmaceutical, Biotechnology, Branches of biology, TLR7, Toll-like receptor, Immunotherapy, Immune system

Today, Primmune Therapeutics announced the close of its Series A financing round with the addition of $4.0 million from Bioqube Ventures, a European life sciences venture capital firm.

Key Points: 
  • Today, Primmune Therapeutics announced the close of its Series A financing round with the addition of $4.0 million from Bioqube Ventures, a European life sciences venture capital firm.
  • This brings the total of the Series A financing raise to $31.4 million.
  • Concurrently, Debbie Dumont, Co-founder and Managing Partner at Bioqube Ventures has joined Primmunes Board of Directors as an observer.
  • Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.